JP5119202B2 - Hemoglobin A1c measuring device - Google Patents
Hemoglobin A1c measuring device Download PDFInfo
- Publication number
- JP5119202B2 JP5119202B2 JP2009123680A JP2009123680A JP5119202B2 JP 5119202 B2 JP5119202 B2 JP 5119202B2 JP 2009123680 A JP2009123680 A JP 2009123680A JP 2009123680 A JP2009123680 A JP 2009123680A JP 5119202 B2 JP5119202 B2 JP 5119202B2
- Authority
- JP
- Japan
- Prior art keywords
- measurement
- hemoglobin
- container
- hba1c
- glycated peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000001554 Hemoglobins Human genes 0.000 title claims description 12
- 108010054147 Hemoglobins Proteins 0.000 title claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 239000002244 precipitate Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 230000001376 precipitating effect Effects 0.000 claims description 7
- 238000002835 absorbance Methods 0.000 claims description 4
- 229960000633 dextran sulfate Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims 1
- 229940043264 dodecyl sulfate Drugs 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 150000003751 zinc Chemical class 0.000 claims 1
- 238000005259 measurement Methods 0.000 description 46
- 239000000523 sample Substances 0.000 description 19
- 238000001556 precipitation Methods 0.000 description 15
- 238000000926 separation method Methods 0.000 description 14
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000000691 measurement method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003219 hemolytic agent Substances 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 238000004611 spectroscopical analysis Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000000593 degrading effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108010043393 protease N Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010004032 Bromelains Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000004698 iron complex Chemical group 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- -1 polyoxyethylene octyl phenyl ether Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Sampling And Sample Adjustment (AREA)
Description
本発明は、ヘモグロビンA1cを高感度で測定する装置に関する。 The present invention relates to an apparatus for measuring hemoglobin A1c with high sensitivity.
糖尿病診断の検査項目として血液中のヘモグロビンA1c(以下HbA1c)の測定が重要視されている。HbA1cはヘモグロビン(Hb)に糖鎖が結合したものであり、臨床的には、血中に存在する総Hb濃度に対するHbA1c濃度の割合が検査値として診断に利用される。HbA1cの測定は、従来クロマトグラフィーを用いて行われてきたが、より簡便な測定法として、免疫比濁法や酵素法を用いた分光的な測定法がある。また、いわゆるセンサーによる検出方法として、電気化学的な信号を検出する方法が特許文献1に開示されている。一方、Hbは幅広い波長の光を吸収し、なおかつ鉄の錯体構造を有するために高い酸化還元電位を示すことが知られている。HbA1cはHbに糖化ペプチドが結合したものであることから、上記の様な測定法においてはHb自身が、目的とするHbA1cに由来する吸光度または電気化学的な信号のS/N比を低下させるノイズを発生する。そのため、分光法を利用した測定法においては、Hbを含有した全血試料の希釈や、光路長を短くすることでHbにより吸収される光量が抑制されHbA1cの測定が可能となる。
Measurement of hemoglobin A1c (hereinafter referred to as HbA1c) in blood is regarded as important as a test item for diabetes diagnosis. HbA1c is obtained by binding a sugar chain to hemoglobin (Hb), and clinically, the ratio of the HbA1c concentration to the total Hb concentration present in blood is used for diagnosis as a test value. Although the measurement of HbA1c has been conventionally performed using chromatography, there are spectroscopic measurement methods using an immunoturbidimetric method and an enzymatic method as simpler measurement methods. Further,
一方で、HbA1cに由来する電気化学的な信号を検出する測定方法においては、Hbに由来する電気的な信号を軽減する有効な手段がなかった。また、分光的な測定方法においては、高倍率に希釈することで測定感度が低下するという問題点があった。 On the other hand, in the measuring method for detecting an electrochemical signal derived from HbA1c, there is no effective means for reducing the electrical signal derived from Hb. Further, the spectroscopic measurement method has a problem in that the measurement sensitivity is lowered by diluting at a high magnification.
本発明では、高分子沈殿剤を用いてHbを沈殿し、ろ過または上澄みを抽出することでHbA1cより糖化ペプチドを遊離したHbを除去して、HbA1c測定における測定精度向上を図る。 In the present invention, Hb is precipitated by using a polymer precipitating agent, and Hb liberated the glycated peptide from HbA1c is removed by filtration or extraction of the supernatant, thereby improving measurement accuracy in HbA1c measurement.
本発明の開示する測定装置によれば、高分子沈殿剤を用いることで温度やpH変化を生じることなく、温和な条件でHbを沈殿/除去して、HbA1c測定における測定精度向上を図ることが可能となる。 According to the measuring device disclosed in the present invention, by using a polymer precipitant, Hb is precipitated / removed under mild conditions without causing a change in temperature and pH, thereby improving measurement accuracy in HbA1c measurement. It becomes possible.
以下に本発明を実施するための望ましい形態を例示する。 The desirable form for implementing this invention is illustrated below.
望ましい実施の形態では、測定試料として全血を利用した、HbA1c濃度を高感度で測定するための方法および装置が提供される。 In a desirable embodiment, a method and an apparatus for measuring HbA1c concentration with high sensitivity using whole blood as a measurement sample are provided.
本発明の測定装置は、試料が導入され、化学反応または物理的な手段によりHbA1cから糖化ペプチドを遊離させる前処理容器と、前処理容器で糖化ペプチドから切断されたHbまたはもとより糖化ペプチドを持たないHbを沈殿する沈殿容器と、沈殿物を測定試料中から除去する沈殿物分離機構と、糖化ペプチドを定量するための測定容器と、測定容器内の試料中の糖化ペプチドを定量する測定機構からなる。一つの容器で複数の容器の機能を兼ねることもできる。容器は溶液を保持できる構造体であれば良く、カップ,フィルタ,膜,チューブなどが望ましい。 The measurement apparatus of the present invention has a pretreatment container in which a sample is introduced and glycated peptide is released from HbA1c by chemical reaction or physical means, and Hb cleaved from the glycated peptide in the pretreatment container or originally has no glycated peptide. It consists of a precipitation container for precipitating Hb, a precipitate separation mechanism for removing the precipitate from the measurement sample, a measurement container for quantifying the glycated peptide, and a measurement mechanism for quantifying the glycated peptide in the sample in the measurement container. . One container can also function as a plurality of containers. The container may be any structure that can hold the solution, and is preferably a cup, filter, membrane, tube, or the like.
測定試料には全血試料を用いる。試料は測定開始前に抗凝固剤や溶血試料により処理されたものであっても良い。反応容器に導入される試料液量は、0.1μL以上が望ましく、最も望ましい実施形態では、10μL以上である。 A whole blood sample is used as a measurement sample. The sample may be processed with an anticoagulant or a hemolyzed sample before the start of measurement. The amount of the sample solution introduced into the reaction vessel is desirably 0.1 μL or more, and in the most desirable embodiment, is 10 μL or more.
前処理容器に測定試料が添加された後、溶血剤およびHbA1cから糖化ペプチドを切り出すための分解酵素が添加され、溶血剤により溶血した試料中のHbA1cから糖化ペプチドが遊離される。この際、溶血剤や分解酵素は予め容器中に保持されていても良い。容器中には、溶血剤や分解酵素の反応を阻害するものでなければ抗凝固剤等の他の試薬が含まれていても良い。溶血剤は、イオン性または非イオン性の界面活性剤,有機溶媒,塩,酵素を用いることができる。界面活性剤としてはポリオキシエチレンオクチルフェニルエーテル(商品名:トリトンX100),ドデシル硫酸ナトリウム(以下SDS),サポニンなどが望ましい。有機溶媒としては、ホルムアルデヒド,ヘキサン,アセトンなどが望ましい。塩としては、塩化アンモニウム,塩化アルミニウムなどが望ましい。より望ましい例は、SDSである。この場合、望ましい濃度は1〜20v/v%である。また、蒸留水で希釈するなど塩濃度の変化により溶血を促しても良い。分解酵素は、HbA1cからHbA1cに固有の糖化ペプチドを遊離することができる酵素を用いることができる。例えば、プロテアーゼ,プロテイナーゼ,エンドヌクレアーゼを挙げることができる。望ましい例は、プロテアーゼXIV(Sigma社),ブロメラインF(天野エンザイム社),プロテアーゼN(天野エンザイム社),プロタメックス(ノボザイム社)などであり、最も望ましくは、プロテアーゼN(天野エンザイム社)である。 After the measurement sample is added to the pretreatment container, a hemolytic agent and a degrading enzyme for cutting out the glycated peptide from HbA1c are added, and the glycated peptide is released from HbA1c in the sample hemolyzed by the hemolytic agent. At this time, the hemolytic agent and the degrading enzyme may be held in the container in advance. The container may contain other reagents such as an anticoagulant as long as it does not inhibit the reaction of a hemolytic agent or a degrading enzyme. As the hemolytic agent, an ionic or nonionic surfactant, an organic solvent, a salt, and an enzyme can be used. As the surfactant, polyoxyethylene octyl phenyl ether (trade name: Triton X100), sodium dodecyl sulfate (hereinafter referred to as SDS), saponin and the like are desirable. As the organic solvent, formaldehyde, hexane, acetone and the like are desirable. As the salt, ammonium chloride, aluminum chloride and the like are desirable. A more desirable example is SDS. In this case, a desirable concentration is 1 to 20 v / v%. In addition, hemolysis may be promoted by a change in salt concentration such as dilution with distilled water. As the degrading enzyme, an enzyme capable of releasing a glycated peptide unique to HbA1c from HbA1c can be used. For example, protease, proteinase, and endonuclease can be mentioned. Desirable examples include protease XIV (Sigma), bromelain F (Amano Enzyme), protease N (Amano Enzyme), Protamex (Novozyme), and most preferably Protease N (Amano Enzyme). is there.
前処理容器における処理が終了した後、前処理溶液中の遊離の糖化ペプチドとHbを含む試料溶液は沈殿容器に移動される。沈殿容器では、試料溶液に沈殿剤が添加され、沈殿剤との反応によりHbが沈殿する。沈殿が生じた反応液は、沈殿物分離機構を通して沈殿が除去され、遊離の糖化ペプチドを含む測定試料が分離される。 After the treatment in the pretreatment container is completed, the sample solution containing free glycated peptide and Hb in the pretreatment solution is moved to the precipitation container. In the precipitation container, a precipitant is added to the sample solution, and Hb is precipitated by reaction with the precipitant. The reaction solution in which the precipitation has occurred is removed through the precipitate separation mechanism, and the measurement sample containing the free glycated peptide is separated.
沈殿剤は、界面活性剤無機塩,有機塩,高分子電解質,タンパク質変性剤およびそれらの混合物を用いることができ、特にアニオン性の界面活性剤と金属塩の組み合わせが望ましい。界面活性剤は、アニオン性の官能基を持ち、Hbと結合して複合体を形成することのできる水溶性の界面活性剤が望ましい。SDSやデキストラン硫酸ナトリウム,ヘパリンナトリウムが望ましく、もっとも望ましくはSDSである。SDSの濃度は100mmol/L以上が望ましく、最も望ましくは、640mmol/L程度である。金属塩は水溶性で、水に溶けて多価金属カチオンを生じるものが望ましい。具体的には、マグネシウム,マンガン,カルシウム,亜鉛,アルミニウム,セシウムなどの塩が用いることができ、最も望ましくは塩化マグネシウムである。濃度は10mmol/L以上が望ましく、最も望ましくは600mmol/L以上である。さらに沈殿性能を向上する目的で、上記SDSと金属塩の混合物に、ポリエチレングリコール(以下PEG)を加えることも効果的である。この場合、PEGの平均分子量は1,000〜10,000程度が望ましく最も望ましくは6,000程度である。濃度は100〜1,000g/Lが望ましい。 As the precipitant, a surfactant inorganic salt, an organic salt, a polyelectrolyte, a protein denaturant and a mixture thereof can be used, and a combination of an anionic surfactant and a metal salt is particularly desirable. The surfactant is preferably a water-soluble surfactant having an anionic functional group and capable of binding to Hb to form a complex. SDS, sodium dextran sulfate and sodium heparin are desirable, and SDS is most desirable. The concentration of SDS is preferably 100 mmol / L or more, and most preferably about 640 mmol / L. The metal salt is preferably water-soluble and soluble in water to produce a polyvalent metal cation. Specifically, a salt of magnesium, manganese, calcium, zinc, aluminum, cesium or the like can be used, and most preferably magnesium chloride. The concentration is desirably 10 mmol / L or more, and most desirably 600 mmol / L or more. Furthermore, for the purpose of improving the precipitation performance, it is also effective to add polyethylene glycol (hereinafter referred to as PEG) to the mixture of SDS and metal salt. In this case, the average molecular weight of PEG is desirably about 1,000 to 10,000, and most desirably about 6,000. The concentration is preferably 100 to 1,000 g / L.
沈殿物分離機構は、糖化ペプチドを含む反応液成分とHbを含む沈殿物を分離できる構造であれば良く、ろ過機構や遠心分離機構,上澄みの抽出機構などが含まれる。ろ過機構は分離したHbによる詰まりを除く目的で複数の孔径のフィルタが積層された構造が望ましい。フィルタはシリンジやチューブのような筒状構造体に備え付けられ、引圧または加圧により分離を促進しても良い。遠心分離機構は小型で定常回転数3,000rpm以上のものが用いることができ、最も望ましくは定常回転数6,000rpm程度のものである。上澄みの抽出機構は、沈殿物を含まない上澄み部分を部分的に吸引することができる機構であれば良く、ピペッタやチューブなどが望ましい。分離を容易にするために吸引部分にさらにフィルタを備えても良い。 The precipitate separation mechanism may be any structure that can separate the reaction solution component containing the glycated peptide and the precipitate containing Hb, and includes a filtration mechanism, a centrifugal separation mechanism, a supernatant extraction mechanism, and the like. The filtration mechanism is preferably a structure in which filters having a plurality of pore sizes are laminated for the purpose of removing clogging due to separated Hb. The filter may be provided in a cylindrical structure such as a syringe or a tube, and separation may be promoted by drawing pressure or pressurization. The centrifugal separation mechanism can be small and has a steady rotation speed of 3,000 rpm or more, and most preferably has a steady rotation speed of about 6,000 rpm. The supernatant extraction mechanism may be any mechanism that can partially suck the supernatant portion that does not contain the precipitate, and is preferably a pipetter or a tube. In order to facilitate the separation, a filter may be further provided in the suction part.
測定機構は、安定して再現性良くHbA1c濃度を定量できる機構であれば良く、測定原理は、分光法,電流法,電圧法,交流インピーダンス法,伝導度法のいずれの方式であっても良い。望ましくは、従来から多くの装置に用いられ測定方法が確立されている分光法や、Hb分離後、少量の試料でも測定が可能な電圧計測方式のセンサーである。 The measurement mechanism may be any mechanism that can stably determine the HbA1c concentration with good reproducibility, and the measurement principle may be any of the spectroscopic method, current method, voltage method, AC impedance method, and conductivity method. . Desirably, it is a spectroscopic method that has been used in many devices and has established a measurement method, or a voltage measurement type sensor that can measure even a small amount of sample after Hb separation.
本発明の開示する装置の最も望ましい実施形態を図1に示す。 The most preferred embodiment of the disclosed device is shown in FIG.
最も望ましい実施形態では、前処理容器1,沈殿容器2,沈殿物分離機構3,測定容器4がフィルタからなり、それらが積層されることで、毛細管現象により容器間の液の移動が行われる。沈殿容器には、沈殿剤が含有されており、試料溶液が沈殿容器へ浸透すると共に沈殿剤と反応して凝固する。凝固したHbは沈殿物分離機構であるフィルタ中の移動速度が著しく低下するため、糖化ペプチドを含む溶液成分が第一に測定容器へ到達する。溶液成分中の糖化ペプチドは測定容器に含まれる反応試薬と反応し反応生成物を生じる。測定容器に接する測定機構5で反応生成物を検出することでHbA1cの定量が可能になる。この場合、測定機構は電気的な信号や吸光度を検出することによりHbA1cを定量するセンサーである。
In the most desirable embodiment, the
沈殿剤組成:試料添加により以下の濃度になるよう、各試薬濃度を調製する。 Precipitant composition: The concentration of each reagent is adjusted to the following concentration by adding the sample.
SDS:640mmol/L
塩化マグネシウム:600mmol/L
PEG:600g/L
SDS: 640 mmol / L
Magnesium chloride: 600 mmol / L
PEG: 600 g / L
以上、測定機構にセンサーを用いたが、測定容器として分光セルを用い、測定機構として分光光度計を用いて分光法により測定を行っても良い(図2)。また、前処理容器および沈殿容器にフィルタを用いたが、カップ状の容器を用いて分注機構により次の容器へ移動(図3)しても良い。さらに、測定試料が沈殿物分離機構を通過するための推進力として、ポンプを用いて引圧(図4)または加圧(図5)することで送液を促しても良い。沈殿物分離機構として、小型の遠心分離を備えることも可能である(図6)。また、Hb測定部とHbA1c測定部を一続きに連結することで、Hbを測定した検体を、そのままHbA1c測定に用いることも可能である(図7)、導入された検体を二つ以上に分割する機構を設けることで、導入された検体を、Hb測定部とHbA1c測定部に分配し、平行して測定することも可能である(図8)。 As described above, the sensor is used as the measurement mechanism. However, the spectroscopic cell may be used as the measurement container, and the spectrophotometer may be used as the measurement mechanism to perform the measurement by spectroscopy (FIG. 2). Moreover, although the filter was used for the pretreatment container and the precipitation container, it may be moved to the next container by a dispensing mechanism using a cup-shaped container (FIG. 3). Further, as a driving force for the measurement sample to pass through the precipitate separation mechanism, liquid feeding may be promoted by pulling (FIG. 4) or pressurizing (FIG. 5) using a pump. As a precipitate separation mechanism, it is possible to provide a small centrifugal separator (FIG. 6). In addition, by connecting the Hb measurement unit and the HbA1c measurement unit in succession, it is possible to use the Hb measured sample as it is for the HbA1c measurement (FIG. 7). The introduced sample is divided into two or more. It is also possible to distribute the introduced sample to the Hb measurement unit and the HbA1c measurement unit and measure them in parallel (FIG. 8).
実施例1:最も望ましい形態による測定値と除去機構を含まない装置の比較
最も望ましい実施形態により、電位差計測方式のセンサーを用いて濃度の異なる全血試料を測定し、検量線を作成した。検量線の傾きを測定感度と定義し、最も望ましい実施形態(実施例1)と、Hb除去機構を含まない形態での感度の比較を行った結果、Hb除去機構を含まない形態では、ネルンストの式から算出される感度の理論値(−59.2mV/dec)と比較して大きく低下し、感度は−4.3mV/decであった(図9)。一方、最も望ましい実施形態では理論値に近い感度−56.3mV/decが得られ(図10)、除去機構を含まない形態での感度と比較して、13倍程度の感度向上が確認された。
Example 1: Comparison of Measurement Value According to Most Desired Form and Apparatus Not Containing Removal Mechanism According to the most desirable embodiment, whole blood samples having different concentrations were measured using a potentiometric sensor, and a calibration curve was prepared. The slope of the calibration curve was defined as the measurement sensitivity, and the sensitivity of the most desirable embodiment (Example 1) and the sensitivity not including the Hb removal mechanism were compared. Compared with the theoretical value (−59.2 mV / dec) of the sensitivity calculated from the equation, the sensitivity was −4.3 mV / dec (FIG. 9). On the other hand, in the most desirable embodiment, a sensitivity close to the theoretical value of -56.3 mV / dec was obtained (FIG. 10), and a sensitivity improvement of about 13 times was confirmed as compared with the sensitivity in the form not including the removal mechanism. .
実施例2:沈殿剤の組成最適化
沈殿剤としてSDSと塩化マグネシウムを用い、それぞれの濃度を振って混合することで、種々の組成の沈殿剤を作製した。各種組成の沈殿剤とHbを含む試料とを反応させ沈殿を生じた後遠心分離を行い、上澄み液に含まれるHb濃度を測定することで、沈殿能力の評価を行った。Hb濃度の測定は吸光度法を用いて行った。結果を図11に示す。SDS濃度が320〜640mmol/L、塩化マグネシウム濃度が300〜600mmol/Lの範囲で、各々の濃度が高いほど残存するHb濃度を減少できる(沈殿させやすい)傾向がみられ、SDS濃度640mmol/L,塩化マグネシウム濃度600mmol/Lで、最も効果的にHbを沈殿することができた。
Example 2: Optimization of precipitant composition SDS and magnesium chloride were used as precipitants, and the precipitants of various compositions were prepared by mixing at different concentrations. Precipitation agent of various compositions was reacted with Hb-containing samples to cause precipitation, followed by centrifugation, and the concentration of Hb contained in the supernatant was measured to evaluate the precipitation ability. The Hb concentration was measured using an absorbance method. The results are shown in FIG. When the SDS concentration is in the range of 320 to 640 mmol / L and the magnesium chloride concentration is in the range of 300 to 600 mmol / L, there is a tendency that the remaining Hb concentration can be decreased (easily precipitated) as the concentration increases, and the SDS concentration is 640 mmol / L. , Hb could be precipitated most effectively at a magnesium chloride concentration of 600 mmol / L.
実施例3:沈殿剤の沈殿能力向上
実施例2で最適化した組成の沈殿剤に対して、タンパク質の沈殿剤として一般的に用いられるPEG(平均分子量6,000)をさらに添加し、実施例2と同様の方法で沈殿能力の評価を行った。結果を図12に示す。PEG濃度が高くなるほど沈殿できるHb濃度は向上し、PEG濃度600g/Lで残存するHbは分光法の検出限界値以下まで減少した。
Example 3: Improving the precipitating ability of the precipitating agent To the precipitating agent having the composition optimized in Example 2, PEG (average molecular weight 6,000) generally used as a protein precipitating agent was further added. The precipitation ability was evaluated in the same manner as in No. 2. The results are shown in FIG. The higher the PEG concentration, the higher the Hb concentration that can be precipitated, and the Hb remaining at a PEG concentration of 600 g / L decreased below the detection limit value of the spectroscopic method.
1 HbA1c用前処理容器
2 Hb沈殿容器
3 沈殿物分離機構
4 HbA1c測定容器
5 HbA1c測定機構
6 Hb測定機構
7 Hb測定容器
8 検体分配機構
1
Claims (3)
前記沈殿剤は、ドデシル硫酸塩,デキストラン硫酸塩,ヘパリン塩からなる群から選択された物質と、マグネシウム塩,カルシウム塩,亜鉛塩からなる群から選択された物質の組合せからなり、
前記フィルタ間は毛細管現象により液の移動が行われることを特徴とするヘモグロビンA1c測定装置。 A filter containing a precipitant that precipitates hemoglobin, a filter that separates the precipitate precipitated by the precipitant and the liquid containing the glycated peptide, and a filter that reaches the liquid containing the glycated peptide are stacked,
The precipitating agent comprises a combination of a substance selected from the group consisting of dodecyl sulfate, dextran sulfate, heparin salt and a substance selected from the group consisting of magnesium salt, calcium salt, zinc salt,
The hemoglobin A1c measuring apparatus is characterized in that liquid is moved between the filters by capillary action.
さらに、該糖化ペプチドを含む液体が到達するフィルタに接し、ヘモグロビンA1cを測定する測定機構を備えることを特徴とするヘモグロビンA1c測定装置。 In the hemoglobin A1c measuring apparatus of Claim 1,
Furthermore, the hemoglobin A1c measuring apparatus is provided with a measuring mechanism for measuring hemoglobin A1c in contact with a filter that the liquid containing the glycated peptide reaches .
前記測定機構は、電気的な信号や吸光度を検出することによりヘモグロビンA1cを定量するセンサーであることを特徴とするヘモグロビンA1c測定装置。 The hemoglobin A1c measuring device according to claim 2,
The hemoglobin A1c measuring apparatus , wherein the measuring mechanism is a sensor that quantifies hemoglobin A1c by detecting an electrical signal or absorbance .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009123680A JP5119202B2 (en) | 2009-01-29 | 2009-05-22 | Hemoglobin A1c measuring device |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009017456 | 2009-01-29 | ||
JP2009017456 | 2009-01-29 | ||
JP2009123680A JP5119202B2 (en) | 2009-01-29 | 2009-05-22 | Hemoglobin A1c measuring device |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010197369A JP2010197369A (en) | 2010-09-09 |
JP5119202B2 true JP5119202B2 (en) | 2013-01-16 |
Family
ID=42822209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009123680A Active JP5119202B2 (en) | 2009-01-29 | 2009-05-22 | Hemoglobin A1c measuring device |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5119202B2 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000300294A (en) * | 1999-04-16 | 2000-10-31 | Dai Ichi Pure Chem Co Ltd | Determination of hemoglobin A1c |
EP2236618A3 (en) * | 2001-01-31 | 2011-06-08 | Asahi Kasei Pharma Corporation | Compositions for assaying glycoprotein |
JP4925384B2 (en) * | 2001-04-20 | 2012-04-25 | 旭化成ファーマ株式会社 | Method for quantifying N-terminal glycated protein |
DE602004030328D1 (en) * | 2003-05-21 | 2011-01-13 | Asahi Kasei Pharma Corp | METHOD OF MEASURING GLYCOLATED HEMOGLOBIN A1C, ENZYME FOR USE AND METHOD FOR THE MANUFACTURE THEREOF |
WO2004111221A1 (en) * | 2003-06-19 | 2004-12-23 | Novozymes A/S | Proteases |
JP4622836B2 (en) * | 2005-12-08 | 2011-02-02 | 王子製紙株式会社 | Analysis equipment |
-
2009
- 2009-05-22 JP JP2009123680A patent/JP5119202B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010197369A (en) | 2010-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3494646B2 (en) | Preparation of nucleic acids from mononuclear cells | |
Worsfold et al. | Characterisation and quantification of organic phosphorus and organic nitrogen components in aquatic systems: a review | |
Baghdadi et al. | In situ solvent formation microextraction based on ionic liquids: a novel sample preparation technique for determination of inorganic species in saline solutions | |
Gustafsson et al. | On the integrity of cross-flow filtration for collecting marine organic colloids | |
Tang et al. | Organic complexation of copper in surface waters of Galveston Bay | |
Shirkhanloo et al. | Dispersive liquid-liquid microextraction based on task-specific ionic liquids for determination and speciation of chromium in human blood | |
EP1992943A1 (en) | Method of determining metal by colorimetry and determination reagent | |
CN103789298A (en) | Erythrocyte lysis buffer and application thereof | |
JP2009013164A (en) | Apparatus for measuring high density lipoprotein, and method for separating the same | |
EP2508863B1 (en) | Method for recovering metal | |
Noorashikin et al. | Determination of phenol in water samples using cloud point extraction and UV spectrophotometry | |
JP5899085B2 (en) | Heavy metal recovery method and heavy metal recovery reagent used therefor | |
Kolorimetri | Molecular weight cut-off determination of pressure filtration membranes via colorimetric detection method | |
JP5119202B2 (en) | Hemoglobin A1c measuring device | |
García-Otero et al. | Assessment of metals bound to marine plankton proteins and to dissolved proteins in seawater | |
Ghaedi et al. | Preconcentration and determination of zinc and lead ions by a combination of cloud point extraction and flame atomic absorption spectrometry | |
Singh et al. | Fabrication and construction of highly sensitive polymeric nanoparticle-based electrochemical biosensor for asparagine detection | |
JP4622836B2 (en) | Analysis equipment | |
Kawaguchi et al. | Simplified capture, extraction, and amplification of cellular DNA from water samples | |
JP6526441B2 (en) | Metal recovery method and metal recovery reagent | |
KR20120050119A (en) | Method and apparatus for quantitative analysis the extent of membrane fouling by using fluorescence protein structures | |
Asman et al. | Triton X-100/β-Cyclodextrin Cloud Point Extraction for Removal of Phenol Using Different of Sodium Salts as Inducing Phase Separation Agent. | |
JP5742639B2 (en) | Glycated protein analyzer and analysis method | |
JP4547327B2 (en) | Analysis method | |
JP7480652B2 (en) | Analysis method for glue in electrolyte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110801 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110801 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120710 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120907 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120925 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121022 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5119202 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151026 Year of fee payment: 3 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |